1 – 2 of 2
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
(
- Contribution to journal › Article
- 2014
-
Mark
Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013
(
- Contribution to journal › Article